durvalumab


( Last Updated : June 14, 2022)
Generic Name:
durvalumab
Project Status:
Pending
Therapeutic Area:
Biliary tract cancer
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0296-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Gastrointestinal
Indications:
In combination with chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.